title: Effect of hypertonic sodium chloride hydroxyethyl starch 40 on ET, TXB2, 6-keto-PGF1α, and ANP of preeclampsia in caesarean section.
abstract: OBJECTIVE
  Preeclampsia is a unique disease of pregnancy. Delivery via caesarean section is the most important way of terminating the pregnancy and treating preeclampsia. Perioperative fluid therapy is performed to maintain the circulatory volume and reduce tissue edema. This study evaluated the effects of hypertonic sodium chloride hydroxyethyl starch 40 (HSH40) as perioperative fluid therapy for preeclampsia patients.
  
  
  METHODS
  Forty preeclamptic women were randomly divided into two groups: the Ringer's solution group and the HSH40 group. Their ECG, HR, MAP, and SPO2 were monitored. Their MVP and HR were recorded at five, eight, and ten minutes after anesthesia induction and at the end of the caesarean section. The corresponding volume of infusion, blood loss, and urine output during the operation were also recorded. Venous samples were collected before HSH40 infusion and 30 min after infusion to measure the plasma concentrations of ET, TXB2, 6-keto-PGF1α, and ANP via a radioimmunoassay.
  
  
  RESULTS
  HSH40 infusion significantly decreased the plasma ET levels (p < 0.01), significantly changed the plasma ANP and TXB2 levels (p < 0.05), and significantly increased the plasma 6-keto-PGF1α levels (p < 0.01) in the experimental group compared with those before infusion. The plasma levels of ET, ANP, TXB2, and 6-keto-PGF1α did not significantly change in the control group. Compared with T1, MAP decreased significantly at T2, T3, T4, and T5 within groups (p < 0.05) and between the two groups. MAP significantly changed at T2, T3, T4, and T5 (p < 0.05). HR did not significant change at T1, T2, T3, T4, and T5 within or between groups. Volume of infusion and urine volume significantly differed between groups (p < 0.05).
  
  
  CONCLUSIONS
  Low-dose HSH40 lowers the plasma levels of vasoconstrictor substances (ET and TXB2) and increases the levels of vasodilator substances (6-keto-PGF1α and ANP) during preeclampsia. It effectively maintains and stabilizes the circulating blood volume, increasing renal blood flow, which improves renal function and increases urine output.
authors: T
authors: T
authors: Wang
authors: l H
authors: lH
authors: Jiang
authors: J B
authors: JB
authors: Zhu
authors: X Y
authors: XY
authors: Wei
authors: L
authors: L
authors: Li
authors: B
authors: B
authors: Liu
mesh_terms: D015121:6-Ketoprostaglandin F1 alpha / Q000097:blood; D000328:Adult; D009320:Atrial Natriuretic Factor / Q000097:blood; D002585:Cesarean Section / Q000379:methods*; D005260:Female; D005440:Fluid Therapy / Q000379:methods; D006801:Humans; D006895:Hydroxyethyl Starch Derivatives / Q000008:administration & dosage*; D007552:Isotonic Solutions / Q000008:administration & dosage*; D019990:Perioperative Care / Q000379:methods; D010952:Plasma Substitutes / Q000008:administration & dosage; D011225:Pre-Eclampsia / Q000097:blood / Q000503:physiopathology / Q000628:therapy; D011247:Pregnancy; D000077331:Ringer's Solution; D012462:Saline Solution, Hypertonic / Q000008:administration & dosage*; D013812:Therapeutics; D013929:Thromboxane B2 / Q000097:blood
chemical_list: D006895:Hydroxyethyl Starch Derivatives; D007552:Isotonic Solutions; D010952:Plasma Substitutes; D012462:Saline Solution, Hypertonic; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha; D000077331:Ringer's Solution; D009320:Atrial Natriuretic Factor